Nicole Toney

Nicole Toney

Auto-generated profile, based on publicly available information

Nicole Toney

Center for Research, Investigation, and Systems Modeling of Acute Illness, and Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Diagnostic Cytopathology
Verified
Journal Article
Open access
PDF file
MLMark A. Lupo
Mark A. Lupo
AWAnn E. Walts
Ann E. Walts
JSJ. Woody Sistrunk
J. Woody Sistrunk
TGThomas J. Giordano
Thomas J. Giordano
PSPeter M. Sadow
Peter M. Sadow
SBShikha Bose
Shikha Bose
Background: Approximately 25% of thyroid nodule fine‐needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Accurate risk stratification of these FNAs with ancillary testing would reduce unnecessary thyroid surgery.Methods: We evaluated the performance of an ancillary multiplatform test (MPTX) that has three diagnostic categories (negative, moderate, and positive). MPTX includes the combination of a mutation panel (ThyGeNEXT®) and a microRNA risk classifier (ThyraMIR®). A blinded, multicenter study was performed using consensus histopathology diagnosis among three pathologists to validate test performance.Results: Unanimous consensus diagnosis was reached in 197 subjects with indeterminate thyroid nodules; 36% had disease. MPTX had 95% sensitivity (95% CI,86%‐99%) and 90% specificity (95% CI,84%‐95%) for disease in prevalence adjusted nodules with Bethesda III and IV cytology. Negative MPTX results ruledout disease with 97% negative predictive value (NPV; 95% CI,91%‐99%) at a 30% disease prevalence, while positive MPTX results ruledin high risk disease with 75% positive predictive value (PPV; 95% CI,60%‐86%). Such results are expected in four out of five Bethesda III and IV nodules tested, including RAS positive nodules in which the microRNA classifier was useful in rulingin disease. 90% of mutation panel false positives were due to analytically verified RAS mutations detected in benign adenomas. Moderate MPTX results had a moderate rate of disease (39%, 95% CI,23%‐54%), primarily due to RAS mutations, wherein the possibility of disease could not be excluded.Conclusions: Our results emphasize that decisions for surgery should not solely be based on RAS or RAS‐like mutations. MPTX informs management decisions while accounting for these challenges.

8 September 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
EFEricka L. Fink
Ericka L. Fink
PKPatrick M. Kochanek
Patrick M. Kochanek
APAshok Panigrahy
Ashok Panigrahy
SBSue R. Beers
Sue R. Beers
RBRachel P. Berger
Rachel P. Berger
CKChristopher Keys
Christopher Keys
Approximately 10 000 children experience in-hospital or out-of-hospital cardiac arrest annually in the US.1,2 Children with return of spontaneous circulation (ROSC) are at high risk of neurological morbidity and death due to global hypoxic-ischemic brain injury.3 Accurate early understanding of the risk of neurological injury could support clinician and family decision-making and treatment. However, a standardized validated approach is lacking.4

1 November 2019 in Diagnostic Cytopathology
Verified
Journal Article
Open access
PDF file
SJSara Jackson
Sara Jackson
GKGyanendra Kumar
Gyanendra Kumar
ABAnna B. Banizs
Anna B. Banizs
NTNicole Toney
Nicole Toney
JSJan F. Silverman
Jan F. Silverman
SFSydney D. Finkelstein
Sydney D. Finkelstein
INTRODUCTION: Focused and expanded mutation panels were assessed for the incremental utility of using an expanded panel in combination with microRNA risk classification.METHODS: Molecular results were reviewed for patients who underwent either a focused mutation panel (ThyGenX®) or an expanded mutation panel (ThyGeNEXT®) for strong and weak oncogenic driver mutations and fusions. microRNA results (ThyraMIR®) predictive of malignancy, including strong positive results highly specific for malignancy, were examined.RESULTS: Results of 12 993 consecutive patients were reviewed (focused panel = 8619, expanded panel = 4374). The expanded panel increased detection of strong drivers by 8% (P < .001), with BRAFV600E and TERT promoters being the most common. Strong drivers were highly correlated with positive microRNA results of which 90% were strongly positive. The expanded panel increased detection of coexisting drivers by 4% (P < .001), with TERT being the most common partner often paired with RAS. It increased the detection of weak drivers, with RAS and GNAS being the most common. 49% of nodules with weak drivers had positive microRNA results of which 33% were strongly positive. The expanded panel also decreased the number of nodules lacking mutations and fusions by 15% (P < .001), with 8% of nodules having positive microRNA results of which 22% were strongly positive.CONCLUSIONS: Using expanded mutation panels that include less common mutations and fusions can offer increased utility when used in combination with microRNA classification, which helps to identify high risk of malignancy in the cases where risk is otherwise uncertain due to the presence of only weak drivers or the absence of all drivers.

1 July 2019 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
NTNicole A. Toney
Nicole A. Toney
MBMichael Bell
Michael Bell
SBSteven H. Belle
Steven H. Belle
RHRegina M. Hardison
Regina M. Hardison
NRNorberto Rodriguez‐Baez
Norberto Rodriguez‐Baez
PGPediatric Acute Liver Failure Study Group
Pediatric Acute Liver Failure Study Group
Background: Pediatric acute liver failure (PALF) is a public heath burden, often requiring prolonged hospitalization and liver transplantation. Hepatic encephalopathy (HE) is a complication of PALF with limited diagnostic tools to predict outcomes. Serum neurological markers (neuron‐specific enolase, S100β, and myelin basic protein) can be elevated in traumatic or ischemic brain injury. We hypothesized that these neuromarkers would be associated with the development of HE in PALF.Methods: PALF study participants enrolled between May 2012 and December 2014 by 12 participating centers were the subjects of this analysis. Daily HE assessments were determined by study investigators. Neurological and inflammatory markers were measured using enzyme‐linked immunosorbent assay and MILLIPLEX techniques, respectively. To model encephalopathy, these markers were log2 transformed and individually examined for association with HE using a generalized linear mixed model with a logit link and random intercept.Results: Eighty‐two children had neurological and inflammatory marker levels and HE assessments recorded, with the majority having assessments for 3 days during their illness. An indeterminate diagnosis (29%) was most common and the median age was 2.9 years. Significant associations were observed for HE with S100β (odds ratio 1.16, 95% confidence interval [1.03–1.29], P = 0.04) and IL‐6 (odds ratio 1.24 [1.11–1.38], P = 0.006).Conclusions: Serum S100β and IL‐6 are associated with HE in children with PALF. Measuring these markers may assist in assessing neurological injury in PALF, impacting clinical decisions.

20 January 2016 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
DLDavid Loren
David Loren
TKThomas Kowalski
Thomas Kowalski
ASAli Siddiqui
Ali Siddiqui
SJSara Jackson
Sara Jackson
NTNicole Toney
Nicole Toney
NHNadim Haddad
Nadim Haddad
Integrated molecular pathology (IMP) approaches based on DNA mutational profiling accurately determine pancreatic cyst malignancy risk in patients lacking definitive diagnoses following endoscopic ultrasound imaging with fine-needle aspiration of fluid for cytology. In such cases, IMP ‘low-risk’ and ‘high-risk’ diagnoses reliably predict benign and malignant disease, respectively, and provide improved risk stratification for malignancy than a model of the 2012 International Consensus Guideline (ICG) recommendations. Our objective was to determine if initial adjunctive IMP testing influenced future real-world pancreatic cyst management decisions for intervention or surveillance relative to ICG recommendations, and if this benefitted patient outcomes. Analysis of data from the previously described National Pancreatic Cyst Registry. Associations between real-world decisions (intervention vs. surveillance), ICG model recommendations (surgery vs. surveillance) and IMP diagnoses (high-risk vs. low-risk) were evaluated using 2 × 2 tables. Kaplan Meier and hazard ratio analyses were used to assess time to malignancy. Odds ratios (OR) for surgery decision were determined using logistic regression. Of 491 patients, 206 received clinical intervention at follow-up (183 surgery, 4 chemotherapy, 19 presumed by malignant cytology). Overall, 13 % (66/491) of patients had a malignant outcome and 87 % (425/491) had a benign outcome at 2.9 years’ follow-up. When ICG and IMP were concordant for surveillance/surgery recommendations, 83 % and 88 % actually underwent surveillance or surgery, respectively. However, when discordant, IMP diagnoses were predictive of real-world decisions, with 88 % of patients having an intervention when ICG recommended surveillance but IMP indicated high risk, and 55 % undergoing surveillance when ICG recommended surgery but IMP indicated low risk. These IMP-associated management decisions benefitted patient outcomes in these subgroups, as 57 % had malignant and 99 % had benign outcomes at a median 2.9 years’ follow-up. IMP was also more predictive of real-world decisions than ICG by multivariate analysis: OR 11.4 (95 % CI 6.0 − 23.7) versus 3.7 (2.4 − 5.8), respectively. DNA-based IMP diagnoses were predictive of real-world management decisions. Importantly, when ICG and IMP were discordant, IMP influence benefitted patients by increasing confidence in surveillance and surgery decisions and reducing the number of unnecessary surgeries in patients with benign disease.

27 April 2024 in CHEST Critical Care
Verified
Journal Article
Open access
COChukwudi A. Onyemekwu
Chukwudi A. Onyemekwu
NPNiall T. Prendergast
Niall T. Prendergast
KPKelly M. Potter
Kelly M. Potter
NTNicole A. Toney
Nicole A. Toney
Seyed NouraieSeyed Nouraie
Seyed Nouraie
TGTimothy D. Girard
Timothy D. Girard
Acute brain dysfunction during sepsis, which manifests as delirium or coma, is common and is associated with multiple adverse outcomes, including longer periods of mechanical ventilation, prolonged hospital stays, and increased mortality. Delirium and coma during sepsis may be manifestations of alteration in systemic metabolism. Because access to brain mitochondria is a limiting factor, measurement of peripheral platelet bioenergetics offers a potential opportunity to understand metabolic changes associated with acute brain dysfunction during sepsis. Are altered platelet mitochondrial bioenergetics associated with acute brain dysfunction during sepsis? We assessed participants with critical illness in the ICU for the presence of delirium or coma via validated assessment measures. Blood samples were collected and processed to isolate and measure platelet mitochondrial oxygen consumption. We used Seahorse extracellular flux to measure directly baseline, proton leak, maximal oxygen consumption rate, and extracellular acidification rate. We calculated adenosine triphosphate-linked, spare respiratory capacity, and nonmitochondrial oxygen consumption rate from the measured values. Maximum oxygen consumption was highest in patients with coma, as was spare respiratory capacity and extracellular acidification rate in unadjusted analysis. After adjusting for age, sedation, modified Sequential Organ Failure Assessment score without the neurologic component, and preexisting cognitive function, increased spare respiratory capacity remained associated with coma. Delirium was not associated with any platelet mitochondrial bioenergetics. In this single-center exploratory prospective cohort study, we found that increased platelet mitochondrial spare respiratory capacity was associated with coma in patients with sepsis. Future studies powered to determine any relationship between delirium and mitochondrial respiration bioenergetics are needed.